Beyond Air (XAIR)

The company’s commercial and development strategy is centred on conditions in which inhaled nitric oxide may have clinical utility. These include pulmonary hypertension, lower respiratory tract infections, and other diseases affecting lung function. By generating nitric oxide on demand, Beyond Air seeks to simplify logistics for hospitals and other care settings while supporting precise dosing for patients who need targeted respiratory treatment.

Beyond Air operates in a specialised segment of the healthcare market that combines regulated medical devices with drug-device therapeutic applications. Its technology must meet safety, efficacy, manufacturing, and clinical-use standards, and the company’s growth depends on regulatory approvals, physician adoption, reimbursement, and continued evidence supporting nitric oxide therapy across its target indications.

The business is distinctive for its attempt to modernise inhaled nitric oxide delivery through a portable generation system. If adopted broadly, the platform could reduce some of the storage and handling constraints associated with conventional nitric oxide cylinders and expand where the therapy can be used. Investors typically view Beyond Air as an early commercial-stage healthcare company with exposure to both medical-device execution and clinical pipeline risk.